New Biosynthetic Psilocybin Hits The Psychedelics Market, Available For Research And Clinical Trials
With psilocybin among the favorites within psychedelics,
Magic Mushrooms Producer Optimi Keeps Betting On The FDA-approval Of Psychedelics
Optimi Health (OTCQX: OPTHF) has released an operational update on its planned year of commercialization, including the launch of psychedelics catalog.
Psychedelics Funding At Its Best: $1.5M Destined To Psilocin Clinical Trials In Australia
Psychedelics biopharma company Lobe Sciences Ltd.
Nasdaq-listed Bright Minds Closes $4 Million Offering And Begins Dosing In Clinical Trial For Epilepsy
Biopharma company developing next-generation mental health treatments Bright Minds Biosciences Inc. (NASDAQ: DRUG) has closed its overnight offering for gross proceeds of approximately $4 million.
This Company Just Created 3 Brand New Psychedelics—Without The Hallucinogenic Side Effects
Mindset Pharma Inc. (OTCQB: MSSTF), a company producing psychedelic and non-psychedelic drugs for mental health conditions has recently identified three additional families of highly novel, non-tryptamine psychedelic compounds.
World Class Leaders In Psychedelics Form Benzinga’s Psychedelic Advisory Council—Get To Know Them
The Benzinga Psychedelics Advisory Council was introduced in March of 2022 with the sustained goal of better informing investors and general audience about the psychedelics financial and business landscape.
4 Psychedelics Companies Post Financial Results: Learn How Field Trip, Wesana, Braxia and Irwin Naturals Performed
Field Trip (NASDAQ: FTRP), Wesana (OTCQB: WSNAF), Braxia (OTC: BRAXF) and
DMT Producer PsyBio And Shrooms Grower Red Light Holland Share Their Most Recent Financial Results
PsyBio Therapeutics (TSXV: PSYB) (OTCQB: PSYBF), a biotech developing medicines based on naturally-occurring psychedelic substances, and mushroom producer Red Light Holland Corp. (OTC Pink: TRUFF) announced the
New Meme MindMed Executes 1:15 Reverse Stock Split
As of today, psychedelics biotech Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) will trade its common shares based on a 1-for-15 reverse shar
MindMed’s First Patient Dosing Clinical Trial With LSD For Treatment Of Generalized Anxiety Disorder
The clinical-stage biopharma company Mind Medicine -also known as MindMed (NASDAQ: MNMD), which recently made headlines reg